Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | CETP | P11597 | 4/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.33 |
| ▸ | MTOR | P42345 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16790461 | 0.81 | ESR2 (0.34) | ESR2PIK3CAMTORMAPK1NR1H2 | |
| SCHEMBL22374272 | 0.79 | PIK3CA (0.44) | GPR119ARDRD2PIK3CAMTOR | |
| SCHEMBL16790426 | 0.78 | HDAC1 (0.39) | DRD2ESR2PIK3CAMTORNR1H2 | |
| SCHEMBL20184050 | 0.77 | PIK3CA (0.44) | GPR119ARDRD2ESR2PIK3CA | |
| SCHEMBL17058898 | 0.74 | ESR2 (0.33) | ESR2PIK3CAMTORNR1H2 | |
| SCHEMBL21520896 | 0.70 | USP30 (0.39) | GPR119ESR2PIK3CAMTORMAPK1 | |
| SCHEMBL18053903 | 0.69 | GPR119 (0.38) | GPR119NR1H2EGLN2 | |
| SCHEMBL31643715 | 0.69 | HSP90AA1 (0.37) | ESR2PIK3CAMTORNR1H2 | |
| SCHEMBL13656966 | 0.68 | GPR119 (0.47) | GPR119DRD2ESR2 | |
| SCHEMBL15187863 | 0.68 | PIK3CA (0.39) | GPR119ESR2PIK3CAMTORMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3077008-B1 | BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS | HAN JIE (CN) | 2023-10-04 | — | — | EP | disclosed |
| US-20200291086-A1 | BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS | Han, Jie (US) | 2020-09-17 | — | — | US | disclosed |
| US-10626156-B2 | Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs | Han, Jie (US) | 2020-04-21 | — | — | US | disclosed |
| US-20150246958-A1 | BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS | BAIKANG (SUZHOU) CO., LTD (CN) | 2015-09-03 | — | — | US | disclosed |
| US-20150246958-A1 | BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS | BAIKANG (SUZHOU) CO., LTD (CN) | 2015-09-03 | — | — | US | disclosed |
| WO-2015081891-A1 | BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS | BAIKANG (SUZHOU) CO., LTD (CN) | 2015-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626156-B2 | Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs | NOS2, EGLN2, HPGD | GPR119 363/4885AR 2446/4885CETP 1036/4885 |
| US-20150246958-A1 | BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS | NOS2, EGLN2, HPGD | GPR119 363/4885AR 2446/4885CETP 1036/4885 |
| US-20200291086-A1 | BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS | NOS2, EGLN2, HPGD | GPR119 363/4885AR 2446/4885CETP 1036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.